Phellamurin (0-10 μg/mL; 48 hours; U2OS and Saos-2 cells) treatment leads to a repression of cell viability in U2OS and Saos-2 cells in a dose-dependent manner[1].
Phellamurin (0-10 μg/mL; 48 hours; U2OS and Saos-2 cells) treatment concentration-dependently promots the apoptosis of U2OS and Saos-2 cells[1].
Phellamurin (0-10 μg/mL; 48 hours; U2OS and Saos-2 cells) treatment declines the ratios of p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR in U2OS and Saos-2 cells[1].
Phellamurin (50 mg/kg/day; intraperitoneal injection; daily; for 21 days; female BALB/c nude mice) treatment represses osteosarcoma tumor growth in vivo. The ratios of p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR are decreased in xenograft in Phellamurin-treated mice[1].
References:
[1]. Hongzhi Zhang, et al. Anti-tumor Efficacy of Phellamurin in Osteosarcoma Cells: Involvement of the PI3K/AKT/mTOR Pathway. Eur J Pharmacol. 2019 Sep 5;858:172477.
[2]. Hung-Yi Chen, et al. Marked Decrease of Cyclosporin Absorption Caused by Phellamurin in Rats. Planta Med. 2002 Feb;68(2):138-41.
[3]. Keiichi Honda, et al. Synergistic or Antagonistic Modulation of Oviposition Response of Two Swallowtail Butterflies, Papilio Maackii and P. Protenor, to Phellodendron Amurense by Its Constitutive Prenylated Flavonoid, Phellamurin. J Chem Ecol. 2011 Jun;37(6):575-81.